By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
.
Atypical antidepressants like agomelatine, which is also sold under the names Valdoxan and Thymanax, are most commonly used to treat major depressive disorder and generalized anxiety disorder. According to one review, it is just as effective as other antidepressants, with similar overall discontinuation rates and fewer withdrawals due to side effects.
It was also found to be as effective as many other antidepressants in another review.
Weight gain, fatigue, liver issues, nausea, headaches, and anxiety are all common side effects. Continuous blood tests are recommended due to potential liver issues. Its utilization isn’t suggested in individuals with dementia or beyond 75 years old. There is conditional proof that it might have less secondary effects than a few different antidepressants.
Agomelatine works by activating melatonin receptors and blocking some serotonin receptors. It was approved for medical use in Australia and Europe. However, its use in the United States is not approved, so efforts to get approval were stopped. An antidepressant used to treat depression, Servier Agomelatine was developed by the pharmaceutical company.
The mind is generally great at ensuring we have enough of the synthetics we want to appropriately work. However, a number of brain chemicals can be altered by depression.
The Global agomelatine market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Given that affective disorders are characterised by abnormal circadian rhythms, the development of antidepressants with melatonin agonist and 5-HT2C antagonist properties may be promising (Germain & Kupfer,). Agomelatine has been shown to be effective in treating major depressive disorders in a number of clinical trials (Kennedy & Emsley, 2006; De Bodinat et al., 0.
It acts as an agonist at melatonergic receptors and an antagonist at 5-HT2C receptors., Lôo et al.; by Olié and Kasper). One way agomelatine is effective in treating depression is by resynchronizing circadian rhythms, which may be due to this novel receptor profile (for a review, see Gorwood, Kasper et al ).
It is interesting to note that agomelatine also exhibits robust antidepressant and anxiety-reducing properties in a variety of animal models.
A new mouse model of a depressive or anxious state induced in rodents by prolonged exposure to exogenous corticosterone (4-pregnen-11b-diol-3,20-dione 21-hemisuccinate) was recently created.
In this model, we demonstrated that chronic treatment with fluoxetine was effective in reversing the flattened circadian rhythm but not in reversing the inhibition of hippocampal neurogenesis or behavioural dysfunction caused by chronic corticosterone (David et al.,).
They first evaluated agomelatine’s antidepressant/anxiety-like activity in the chronic corticosterone animal model of a depressive/anxiety-like state because it has a different mechanism of action than the antidepressants that are currently available.
In various paradigms like the open-field paradigm (OF), novelty suppressed feeding (NSF), the splash test (ST), the forced swim test (FST), and the coat state, we compared the behavioural effects of chronic agomelatine (10 or 40 mg/kg.d) or fluoxetine .
They also investigated whether agomelatine reversed the flattened circadian rhythm in chronic corticosterone-treated mice, given that mood disorders are often associated with circadian rhythm desynchronization.
